Labiotech.eu
Labiotech.eu is a Berlin-based B2B digital media publisher covering the European biotech industry since 2014. It serves biotech companies, investors, researchers, and pharma firms via daily editorial, the Beyond Biotech Podcast, knowledge-hub trackers, and newsletters, monetized through advertising, sponsored content, and subscriptions.
- Company typePrivate
- Founded2014
- HeadquartersBerlin, Germany
- Headcount11–50
- GTM typeB2B
- OfferingDigital Commerce or Content
What Labiotech.eu does
Labiotech.eu is a Berlin-headquartered B2B digital media company that has operated since 2014 as a specialized publisher covering the European biotechnology industry. The platform delivers editorial coverage of biotech funding, clinical trials, partnerships, regulatory developments, and therapeutic-area advances through daily news articles, in-depth features, expert commentary, and the Beyond Biotech Podcast. Underlying technology is a web-based editorial CMS with podcast distribution infrastructure (Apple Music, Spotify, Buzzsprout), email newsletter delivery, and a growing set of structured knowledge-hub resources including dedicated trackers for biotech funding, deals, layoffs, and events. Labiotech.eu serves four primary segments: biotech and biopharma companies, investors and financial professionals tracking deal flow, life sciences researchers and academics, and large pharmaceutical firms monitoring the innovation landscape. Customer concentrations extend across EMEA and into the US market. The company operates as Labiotech UG (haftungsbeschränkt), a German private limited company, and is a subsidiary of Inpart.
Labiotech.eu firmographics
Firmographics- Name
- Labiotech.eu
- Legal name
- Labiotech UG (haftungsbeschränkt)
- Website
- https://labiotech.eu
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Labiotech.eu is a Berlin-based B2B digital media publisher covering the European biotech industry since 2014. It serves biotech companies, investors, researchers, and pharma firms via daily editorial, the Beyond Biotech Podcast, knowledge-hub trackers, and newsletters, monetized through advertising, sponsored content, and subscriptions.
- Ownership category
- akta.pro rank
Labiotech.eu industry classification
Industry- Product category
- Biotech Industry Digital Media
- SIC
- Periodicals: Publishing Or Publishing & Printing (2721)
- akta.pro primary industry
- Scientific & Laboratory Reference (Chemistry, Biology, Physics; Methods & Protocols) (EDAGAGAG)
Keywords
Where Labiotech.eu is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Labiotech.eu business model
Business model- GTM type
- B2B
- Offering type
- Digital Commerce or Content
- Cost components
- Personnel, Marketing or Sales, Technology or R&D, Operations
Revenue model
- Advertising and Sponsored Content: Labiotech.eu generates revenue primarily through sponsored articles, advertising placements, and sponsored content partnerships with biotech companies, CDMOs, pharmaceutical companies, and industry service providers. Companies like Cryoport Systems, Lonza, Lexogen, and ICEX-Invest in Spain advertise through the platform.
- Subscription/Premium Content: The platform offers premium content behind paywalls, requiring users to subscribe for full access. The website indicates locked content that requires subscription to continue reading, suggesting a freemium or subscription model for certain in-depth articles.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Labiotech.eu product offering
Product offeringCore offering
Labiotech.eu is a B2B digital media platform covering the European biotechnology industry. It publishes daily news articles, in-depth features, industry analysis, podcasts, and newsletters aimed at biotech professionals, investors, and pharma companies, and monetizes through advertising and sponsored content. It also operates tracking tools for biotech funding, deals, layoffs, events, grants, and associations as part of its "Knowledge Hub" resource offering.
Product overview
Labiotech.eu is Europe's leading biotech news platform offering a unified content ecosystem with news articles, in-depth analysis, podcasts, and specialized knowledge hub tools. The core product is the news platform itself, supplemented by the Beyond Biotech Podcast series, and complemented by tracking tools for biotech funding, deals, and layoffs, plus resources for biotech events, grants, and associations. The newsletter provides email-based content delivery. All offerings function together as a comprehensive information resource for the global life sciences community.
Differentiator
Problem solved
Functional benefit
Products and services
- Labiotech.eu News Platform A web-based biotech industry news platform delivering editorial articles, in-depth features, and expert opinion pieces on biotechnology topics including funding, clinical trials, partnerships, M&A, and regulatory developments for biotech and life sciences professionals.
- Beyond Biotech Podcast A podcast series covering biotech industry topics with interviews of industry leaders and discussions on emerging trends, technologies, and companies in the life sciences sector; distributed via Apple Music, Spotify, and Buzzsprout.
- Labiotech Newsletter A recurring email newsletter that delivers the latest biotech industry news, funding updates, and analysis directly to subscribers' inboxes, driving engagement and return visits.
- Sponsored Content and Advertising A B2B advertising and sponsored content offering that allows biotech companies, CDMOs, and pharmaceutical firms to place sponsored articles and advertising on Labiotech.eu for access to its life sciences audience.
Companies that use Labiotech.eu
Customer profileSegments4 records
Ideal customer profiles4 records
Labiotech.eu technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Labiotech.eu partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- InpartcoreInpart is the parent company of Labiotech.eu. The partnership involves content collaboration including the 'Biotech Perspective' report series and referral traffic through Inpart's network connecting accelerators, startups, academia, and investors with biotech companies for collaborative opportunities.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Labiotech.eu competitors and assessment
Company assessmentDirect peers
- BioSpace: BioSpace is a leading digital media platform covering the biotech and pharmaceutical industries with news, job listings, and industry intelligence. It is directly comparable as a B2B biotech news and careers destination serving the same biotech professional audience as Labiotech, though with a stronger US focus.
- Endpoints News: Endpoints News is a digital biotech news publication founded by veteran journalist John Carroll covering drug development, biotech business, and industry deals. It is directly comparable to Labiotech as a daily B2B biotech news outlet monetized through subscriptions and advertising targeting biotech and pharma professionals.
- Fierce Biotech: Fierce Biotech is a long-established biotech industry news brand within the Fierce Pharma network, covering R&D, clinical trials, manufacturing, and business news. It competes directly with Labiotech for pharma and biotech readership and advertising dollars, though it operates as part of a broader B2B media portfolio.
- BioCentury: BioCentury is a subscription-based B2B intelligence provider covering biotech strategy, business, and science for investors and pharma BD teams. It is directly comparable to Labiotech in audience (biotech investors, pharma executives) and product model (deep industry coverage plus proprietary analysis), with a stronger paywalled subscription business.
- Genetic Engineering & Biotechnology News (GEN): GEN is a long-running biotech industry publication covering drug discovery, bioprocessing, omics, and translational research. It is comparable to Labiotech as a multi-format B2B biotech media outlet serving scientists, biotech executives, and investors with news and analysis.
- BioWorld (Clarivate): BioWorld is a subscription-based biotech news and intelligence service owned by Clarivate, covering clinical trials, regulatory, and business developments. It directly competes with Labiotech in serving biotech and pharma professionals with paid news intelligence, though it is part of a much larger data analytics parent.
Broad incumbents
- Drug Discovery & Development: Drug Discovery & Development is an industry publication covering drug R&D, lab technology, and translational research. It is comparable to Labiotech in covering biotech R&D topics, but operates more as a general industry trade outlet under the Informa/Informa Markets portfolio rather than a focused daily news brand.
- MedCity News: MedCity News covers healthcare innovation, digital health, biotech, and life sciences investing. It overlaps with Labiotech in biotech business and funding coverage but extends to broader healthcare and digital health topics, making it a broader-incumbent peer rather than a direct biotech-specialist.
Emerging players
- Bio-IT World: Bio-IT World covers the intersection of informatics, computing, and biotechnology, including AI in drug discovery and clinical research. It is comparable to Labiotech in covering emerging biotech technology themes but with a narrower specialization in the informatics and computational biology niche.
- BioPharma Reporter: BioPharma Reporter covers biopharmaceutical manufacturing, processing, and industry business developments. It shares biotech industry news coverage with Labiotech but with a manufacturing and bioprocessing specialization, making it an adjacent rather than direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Labiotech.eu social profiles
Digital presenceLabiotech.eu financial estimates
Financial estimateRevenue estimate
Valuation estimate
Labiotech.eu leadership team
Management profileNumber of profiles
Profiles1 record
Labiotech.eu funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Labiotech.eu M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Labiotech.eu
What does Labiotech.eu do?
Labiotech.eu is a B2B digital media platform covering the European biotechnology industry. It publishes daily news articles, in-depth features, industry analysis, podcasts, and newsletters aimed at biotech professionals, investors, and pharma companies, and monetizes through advertising and sponsored content. It also operates tracking tools for biotech funding, deals, layoffs, events, grants, and associations as part of its "Knowledge Hub" resource offering.
Is Labiotech.eu a public or private company?
Labiotech.eu is a private company. It is classified as corporate owned and is currently operating.
When was Labiotech.eu founded?
Labiotech.eu was founded in 2014. It employs 11 to 50 people.
Where is Labiotech.eu based?
Labiotech.eu is headquartered in Berlin, Germany, in the Europe region.
How does Labiotech.eu make money?
Two revenue lines are on record. Advertising and Sponsored Content is the primary driver. The others are subscription/Premium Content.
Who are Labiotech.eu's main competitors?
Direct peers on record are BioSpace, Endpoints News, Fierce Biotech, BioCentury, Genetic Engineering & Biotechnology News (GEN) and BioWorld (Clarivate). Broad incumbents are Drug Discovery & Development and MedCity News. Emerging players are Bio-IT World and BioPharma Reporter.
Does Labiotech.eu have an API?
No public API is recorded for Labiotech.eu.
What industry is Labiotech.eu in?
Labiotech.eu's product category is Biotech Industry Digital Media. Its primary akta.pro industry code is EDAGAGAG, Scientific & Laboratory Reference (Chemistry, Biology, Physics; Methods & Protocols). Its SIC code is 2721.